Jazz Pharmaceuticals
JAZZ
441 hedge funds and large institutions have $8.74B invested in Jazz Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 59 funds opening new positions, 148 increasing their positions, 167 reducing their positions, and 50 closing their positions.
77% more call options, than puts
Call options by funds: $270M | Put options by funds: $153M
18% more first-time investments, than exits
New positions opened: 59 | Existing positions closed: 50
13% more funds holding in top 10
Funds holding in top 10: 8 → 9 (+1)
1% more funds holding
Funds holding: 437 → 441 (+4)
1% more capital invested
Capital invested by funds: $8.69B → $8.74B (+$44.9M)
0.2% less ownership
Funds ownership: 94.6% → 94.4% (-0.2%)
11% less repeat investments, than reductions
Existing positions increased: 148 | Existing positions reduced: 167
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$245M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
+$136M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$110M |
| 4 |
Franklin Resources
San Mateo,
California
|
+$79M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$65.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Sarissa Capital Management
Greenwich,
Connecticut
|
-$153M |
| 2 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
-$130M |
| 3 |
Holocene Advisors
New York
|
-$110M |
| 4 |
American Century Companies
Kansas City,
Missouri
|
-$73.8M |
| 5 |
Renaissance Technologies
New York
|
-$71.8M |
JAZZ Hedge Fund Activity: Q1 2021 in Review
441 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Jazz Pharmaceuticals (JAZZ) for Q1 2021, worth a combined $8.74B — up 0.52% from $8.69B a quarter earlier.
Buyers outnumbered sellers: 59 funds opened new JAZZ positions and 50 closed out — a net gain of 9 holders — while 148 added to existing stakes and 167 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $245M. The largest seller was Sarissa Capital Management, cutting an estimated $153M.
- 441 institutional investors held Jazz Pharmaceuticals (JAZZ) as of Q1 2021, up from 437 in Q4 2020.
- Funds reported $8.74B of Jazz Pharmaceuticals stock for Q1 2021, up 0.52% quarter-over-quarter.
- 59 funds opened new Jazz Pharmaceuticals positions in Q1 2021 and 50 closed out, a net change of +9 holders.
- The largest Jazz Pharmaceuticals buyer in Q1 2021 was Wellington Management Group, an estimated $245M added.
- The largest Jazz Pharmaceuticals seller in Q1 2021 was Sarissa Capital Management, an estimated $153M sold.
Based on aggregated 13F filings for Q1 2021.